loader
Please Wait
Applying Filters...
Close
4

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Dasabuvir Sodium, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Dasabuvir Sodium

    APIs // Active Pharmaceutical Ingredients

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    PATENTS

    DIGITAL CONTENT

    PharmaCompass

    PharmaCompass Sponsored Ads

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    1. Also known as: 1132940-11-4, Dasabuvir sodium anhydrous, N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide sodium salt, Sodium (6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)(methylsulfonyl)amide, Chebi:85179, Q27158387
    Molecular Formula
    C26H26N3NaO5S
    Molecular Weight
    515.6  g/mol
    InChI Key
    VZCGKKLFRJCTFM-UHFFFAOYSA-N
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    sodium;[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]-methylsulfonylazanide
    2.1.2 InChI
    InChI=1S/C26H26N3O5S.Na/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18;/h6-15H,1-5H3,(H,27,30,31);/q-1;+1
    2.1.3 InChI Key
    VZCGKKLFRJCTFM-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)[N-]S(=O)(=O)C)N4C=CC(=O)NC4=O.[Na+]
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. 1132940-11-4

    2. Dasabuvir Sodium Anhydrous

    3. N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide Sodium Salt

    4. Sodium (6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)(methylsulfonyl)amide

    5. Chebi:85179

    6. Q27158387

    7. Sodium {6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl]naphthalen-2-yl}(methanesulfonyl)azanide

    8. Sodium;[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]-methylsulfonylazanide

    2.3 Create Date
    2014-12-27
    3 Chemical and Physical Properties
    Molecular Weight 515.6 g/mol
    Molecular Formula C26H26N3NaO5S
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count6
    Exact Mass515.14908639 g/mol
    Monoisotopic Mass515.14908639 g/mol
    Topological Polar Surface Area102 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity944
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

    For hepatitis C virus (HCV) genotype specific activity.

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    J05AP09

    Post Enquiry
    POST ENQUIRY